WO2012138043A3 - Therapeutic composition containing endothelin as an active component - Google Patents

Therapeutic composition containing endothelin as an active component Download PDF

Info

Publication number
WO2012138043A3
WO2012138043A3 PCT/KR2011/010320 KR2011010320W WO2012138043A3 WO 2012138043 A3 WO2012138043 A3 WO 2012138043A3 KR 2011010320 W KR2011010320 W KR 2011010320W WO 2012138043 A3 WO2012138043 A3 WO 2012138043A3
Authority
WO
WIPO (PCT)
Prior art keywords
endothelin
preventing
composition
disease
ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/010320
Other languages
French (fr)
Other versions
WO2012138043A2 (en
Inventor
Eun Ju Lee
Hyo Soo Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seoul National University Hospital
Original Assignee
Seoul National University Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seoul National University Hospital filed Critical Seoul National University Hospital
Publication of WO2012138043A2 publication Critical patent/WO2012138043A2/en
Publication of WO2012138043A3 publication Critical patent/WO2012138043A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a composition for preventing or treating ischemic disease comprising endothelin or a nucleotide sequence encoding endothelin as an active ingredient, and more particularly to a composition for preventing or treating ischemic heart disease, myocardial infarction, angina pectoris, lower limb artery ischemia, distal limb ischemia and ischemic cerebrovascular disease, wherein the composition is administered by intramuscular injection. According to the present invention, administering endothelin-1 by intramuscular injection may efficiently inhibit the progress of ischemia, fibrosis and tissue necrosis, and induce angiogenesis, such that it is promising for preventing or treating the ischemic disease.
PCT/KR2011/010320 2011-04-04 2011-12-29 Therapeutic composition containing endothelin as an active component Ceased WO2012138043A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110030465A KR101418941B1 (en) 2011-04-04 2011-04-04 Therapeutic Composion Containing Endothelin as an Active Component
KR10-2011-0030465 2011-04-04

Publications (2)

Publication Number Publication Date
WO2012138043A2 WO2012138043A2 (en) 2012-10-11
WO2012138043A3 true WO2012138043A3 (en) 2012-11-29

Family

ID=46969630

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/010320 Ceased WO2012138043A2 (en) 2011-04-04 2011-12-29 Therapeutic composition containing endothelin as an active component

Country Status (2)

Country Link
KR (1) KR101418941B1 (en)
WO (1) WO2012138043A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2817638C2 (en) * 2022-08-03 2024-04-17 Юрий Валентинович Червяков Method of treating chronic lower limb ischemia of ii and iii degree of atherosclerotic genesis in occluding lesions of aorto-femoral segment

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5498571B2 (en) 2009-04-30 2014-05-21 ミッドウェスタン ユニバーシティ A novel treatment method using a centerkin
CN113384701A (en) 2013-07-08 2021-09-14 美国中西部大学 Compositions and methods for treating neuropsychiatric disorders using endothelin-B receptor agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104976A1 (en) * 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
WO2007112069A2 (en) * 2006-03-23 2007-10-04 Amylin Pharmaceuticals, Inc. Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
US20100209433A1 (en) * 2005-12-01 2010-08-19 B.R.A.H.M.S Aktiengesellschaft Methods for the diagnosis and for the treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104976A1 (en) * 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
US20100209433A1 (en) * 2005-12-01 2010-08-19 B.R.A.H.M.S Aktiengesellschaft Methods for the diagnosis and for the treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
WO2007112069A2 (en) * 2006-03-23 2007-10-04 Amylin Pharmaceuticals, Inc. Endothelin and endothelin receptor agonists in the treatment of metabolic diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HO, M. C. Y. ET AL.: "Endothelin-1 protects astrocytes from hypoxic/ischemic injury.", THE FASEB JOURNAL., vol. 15, 2001, pages 618 - 626 *
MIMA, T. ET AL.: "Endothelin acts in feline and canine cerebral arteries from the adventitial side.", STROKE., vol. 20, 1989, pages 1553 - 1556 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2817638C2 (en) * 2022-08-03 2024-04-17 Юрий Валентинович Червяков Method of treating chronic lower limb ischemia of ii and iii degree of atherosclerotic genesis in occluding lesions of aorto-femoral segment

Also Published As

Publication number Publication date
KR101418941B1 (en) 2014-07-15
KR20120112894A (en) 2012-10-12
WO2012138043A2 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
SV2016005145A (en) CYCLIC POLIPEPTIDES FOR THE TREATMENT OF CARDIAC INSUFFICIENCY
WO2013142817A3 (en) Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CL2014000504A1 (en) Compounds derived from substituted condensed pyrimidines; preparation procedure; pharmaceutical composition; and use in the treatment and / or prevention of heart failure, angina pectoris, hypertension, among other diseases.
EA201291234A1 (en) ANALOGUE GLUACAGONA
CA2797033C (en) Highly active polypeptides and methods of making and using the same
EA201490521A1 (en) OPTIONS OF FIBROBLAST GROWTH FACTOR 21
CL2015000120A1 (en) Compounds derived from 5-aminotetrahydroquinolin-2-carboxylic acids; preparation process of said compounds; medicine that contains them; and its use for the treatment and / or prevention of pulmonary hypertension, heart failure, angina pectoris, hypertension, thromboembolic diseases, fibrotic diseases, ischemia, among others.
PH12013500011A1 (en) Napht-2-ylacetic acid derivatives to treat aids
WO2012160180A3 (en) Pharmaceutical composition for administration to nails
CL2011001060A1 (en) Compounds derived from 4- [3- {3- (1,2,4-oxadiazol-5-yl) -1h-pyrazol-1-yl} -methyl] -pyridine, 3- [3- {3- (1, 2,4-oxadiazol-5-yl) -1h-pyrazol-1-yl} -methyl) -phenyl, 3- [3- {3- (1,2,4-oxadiazol-5-yl) -1h-pyrazole -1-yl} -methyl) -phenyl; preparation procedure; pharmaceutical composition; Useful to treat cancerous or tumor diseases.
CU20140097A7 (en) SYNTHETIC APELINE MIMETICS FOR THE INSUFFICIENCY TREATMENT
MY188182A (en) Acylated glucagon analogues
EA201691759A1 (en) COMPOSITIONS AND METHODS OF TREATMENT OF PULMONARY HYPERTENSION
WO2011097335A3 (en) Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
WO2012116176A3 (en) Asymmetric ureas and medical uses thereof
TW201613932A (en) Organic compounds
WO2012006516A3 (en) Protein kinase c activators and anticoagulant for the treatment of stroke
MX2012005013A (en) PTEROSTILBEN (PETER) FOR USE IN THE PREVENTION AND / TREATMENT OF SKIN DISEASES, DAMAGES OR INJURIES.
MX2012003324A (en) Glycine compound.
CO2018012258A2 (en) Mic-1 compounds and uses of these
MX384378B (en) THERAPEUTIC DOSAGE OF A NEUROREGULIN OR A SUBSECENCE THEREOF FOR THE TREATMENT OR PROPHYLAXIS OF HEART FAILURE.
ECSP13012812A (en) IMMUNOSUPPRESSOR FORMULATIONS
WO2011146922A3 (en) Materials and methods for treatment of inflammation
WO2012026813A3 (en) Analogs of geranylgeranylacetone and uses thereof
AU2014362144A2 (en) 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11862870

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11862870

Country of ref document: EP

Kind code of ref document: A2